MIDLOTHIAN, Va., Sept. 29, 2021 /PRNewswire/ -- Pulmotect reported positive topline results from their randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with ...
MIDLOTHIAN, Va., May 7, 2020 /PRNewswire/ -- This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect's PUL-042, an inhaled immunomodulatory agent to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback